Quantum Biopharma Ltd. - Class B Subordinate Voting Shares (QNTM)

Quantum BioPharma (NASDAQQNTM) (CSE: QNTM) is a biopharmaceutical company committed to developing innovative solutions to address neurodegenerative and metabolic disorders, as well as alcohol misuse. The company’s portfolio includes groundbreaking therapeutic candidates such as Lucid-MS, a patented compound targeting multiple sclerosis, and consumer-focused products like unbuzzd(TM), a novel alcohol detoxification beverage. Through strategic investments and a focused R&D model, Quantum BioPharma seeks to deliver meaningful health improvements while maximizing shareholder value.

Awards in favour of Quantum BioPharma Total Approximately $3 Million

Quantum BioPharma Ltd. Dual Lists on Upstream's Global Securities Trading App

Trading to become available January 14th under 'QNTM'

TORONTO, ON / ACCESSWIRE / December 20, 2024 / Quantum BioPharma Ltd. (NASDAQQNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), is pleased to announce that after receiving approval from the Board of Directors, the Company has purchased USD $1,000,000 Bitcoin (BTC) and other cryptocurrencies as part of its strategic efforts. As well, going forward the Company will allow for future financing and other transactions to be carried out in cryptocurrency.

TORONTO, ON / ACCESSWIRE / December 10, 2024 / Quantum BioPharma Ltd. (NASDAQQNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announces through its subsidiary, HUGE Biopharma Australia Pty Ltd., that the safety review committee recommends commencing dosing of the second cohort in its trial entitled "A Phase 1, Randomised, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of Lucid-21-302 in Healthy Adult Participants." The safety review committee made this recommendation after reviewing safety and pharmacokinetic data from participants in the first cohort.

TORONTO, ON / ACCESSWIRE / November 25, 2024 / Quantum BioPharma Ltd. (NASDAQQNTM)(CSE:QNTM)(FRA:0K91) (the "Company") formerly named FSD Pharma Inc. (Nasdaq:HUGE)(CSE:HUGE) is pleased to follow up on recent events concerning the complaint filed by the Company in the United States courts, that alleges that CIBC World Markets, RBC Dominion Securities and others (the "Defendants") engaged in market manipulation in the share price of the Company. The Company, as well as its shareholders, have suffered financial and emotional losses resulting from this alleged manipulation. We are determined to right this wrong by the Defendants and reverse the Company losses and claim punitive damages to the extent determined by the courts. As a result, prominent legal teams have been assembled to pursue the recovery of all losses and damages impacting our Company. The law firms have agreed to be compensated without cost to the Company but solely on a contingency basis, meaning that the Company will not be billed for legal costs in this matter. The Company itself is seeking damages of more than US$700M we believe it has suffered. The shareholders can find updated information about the case on the Quantum vs Banks page of our website which will be updated periodically.

TORONTO, ON / ACCESSWIRE / October 29, 2024 / Quantum BioPharma Ltd. (NASDAQQNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announces through its subsidiary, HUGE Biopharma Australia Pty Ltd., that sentinel dosing has started for its trial entitled "A Phase 1, Randomised, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of Lucid-21-302 in Healthy Adult Participants."

To assist enquiries the copy of the complaint can be viewed by clicking the following link: Quantum Bio Pharma Complaint

Christian Attar Law Firm and Freedman Normand Friedland LLP, in conjunction with forensic investigators, have uncovered evidence of a potential multi-year market manipulation scheme that has caused substantial damages to the Company and its shareholders

As the health and wellness sector gains momentum, consumers are increasingly seeking products that can aid recovery from the effects of alcohol. Quantum BioPharma Ltd. (NASDAQQNTM) (CSE: QNTM), a company focused on developing innovative health solutions, is well-positioned to meet this demand with its groundbreaking product designed to support the body in metabolizing alcohol.

TORONTO, ON / ACCESSWIRE / October 7, 2024 / Quantum BioPharma Ltd. (NASDAQQNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma"), provides an update by way of a news release issued by Celly Nutrition Corp. ("Celly Nu"), and its launching of unbuzzd™, an innovative beverage product that is scientifically formulated from a proprietary blend of vitamins, minerals and botanical extracts designed to support the body's natural processes for metabolizing alcohol and promoting alertness.

TORONTO, ON / ACCESSWIRE / September 27, 2024 / Quantum BioPharma Ltd. (formerly, FSD Pharma Inc.) (NASDAQQNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce the following corporate updates.

TORONTO, ON / ACCESSWIRE / September 25, 2024 / Quantum BioPharma Ltd. (formerly, FSD Pharma Inc.) (NASDAQQNTM) (CSE:QNTM) (FRA:0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce that Jason Sawyer, Head of Finance and Mergers and Acquisitions, will present at the ArcStone-Kingswood Growth Summit held on September 26, 2024, in Toronto, ON. The event will feature over 30 public and private companies and 47 sponsors from around the world.

TORONTO, ON / ACCESSWIRE / September 6, 2024 / Quantum BioPharma Ltd. (formerly, FSD Pharma Inc.) (NASDAQQNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, is pleased to announce that it has received a formal notice from The Nasdaq Stock Market, LLC ("Nasdaq") stating that the Company has regained compliance with the minimum bid price requirement set forth in Rule 5550(a)(2) of the Nasdaq Listing Rules. Quantum BioPharma is now in compliance with all applicable listing standards and will continue to be listed and traded on the Nasdaq.

LOS ANGELES, CA / ACCESSWIRE / August 30, 2024 / Quantum BioPharma Ltd. (QNTM) marks a significant milestone with the successful launch of unbuzzd™ on Amazon. This development coincides with the Company's rebranding and ticker change to QNTM. Additionally, recent ethics approval in Australia for a Phase-1 study of Lucid-MS represents a crucial advancement in the development of a novel treatment for Multiple Sclerosis.

TORONTO, ON / ACCESSWIRE / August 30, 2024 / Quantum BioPharma Ltd. (NASDAQQNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announces that highly-anticipated launch of unbuzzd™, a groundbreaking product designed to help individuals recover from the adverse effects of alcohol consumption and prepare for what's next. unbuzzd™ Clear Eyed Citrus Powder Sticks are now available on Amazon.com.

Quantum BioPharma Ltd. (NASDAQQNTM) (CSE: QNTM), formerly FSD Pharma Inc., a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, has finalized its previously announced name change and consolidation. According to the announcement, the company’s class B subordinate voting shares began trading today under the new ticker symbol QNTM. In addition, the company closed on a nonbrokered private placement and issued four postconsolidation Class A multiple voting shares for $18 per share, resulting in gross proceeds of $72. Xorax Family Trust, a trust of which Quantum BioPharma CEO and cochair Zeeshan Saeed is a beneficiary, and Fortius Research and Trading Corp., a corporation of which Quantum BioPharma cochair Anthony Durkacz is a director, purchased all the class a multiple voting shares.